Navigation Links
DSM and LibraGen Sign Agreement to Co-Develop Transaminases for Production of Chiral Amines

PARSIPPANY, N.J., VIENNA, Austria and TOULOUSE, France, Sept. 16 /PRNewswire/ -- DSM and LibraGen, a bacterial diversity-based process and discovery specialist, announced today that they have signed an agreement to co-develop new omega-transaminases for production of chiral amines. Under the terms of the partnership, LibraGen will use its proprietary enzyme discovery and development to identify new enzymes for efficient conversion of a large spectrum of ketons into optically pure R- and S-amines, a compound class highly relevant for fine chemicals and pharmaceuticals industries.

DSM will produce the enzymes at industrial scale using DSM's fermentation capabilities and proprietary expression platform, PluGbug(TM). LibraGen will sell the enzymes in kit form and both parties will use them for screening activities and the development of biocatalytic processes for third parties.

"This collaboration with LibraGen grows the number of available large-scale biocatalysts and will contribute to increasing competitiveness of the transaminase technology for production of chiral amines," said Oliver May, Competence Manager Biocatalysis at DSM Pharmaceutical Products. "In addition, by combining LibarGen's enzyme discovery and DSM's manufacturing capabilities the development timelines from enzyme discovery and screening to final product delivery to our customers will be significantly reduced," said Ronald Gebhard, R&D Director at DSM Pharmaceutical Products.

"We are delighted that we have signed this partnership with DSM," said Renaud Nalin, CEO of LibraGen. "It marks another step forward in the development of LibraGen's industrial biocatalysis capabilities. Customers of DSM and LibraGen will be able to use these new enzymes on a laboratory or industrial production scale to produce intermediates and APIs, thus making our response to market demands even more effective."

LibraGen expects this alliance to bring the company additional openings to provide its services to the fine chemicals, pharmaceutical and cosmetics customers, and to develop and optimize enzymatic synthesis processes for complex molecules.

Financial details of the collaboration were not disclosed.

About LibraGen

LibraGen, Toulouse, France, specializes in the development of innovative bioprocesses for molecule synthesis using biocatalysis for fine chemicals, cosmetics and pharmaceutical industries. One of LibraGen's key assets is its ability to look for high performance enzymes in bacteria populations that have not previously been explored and convert them into production tools. By combining the skills needed to go from R&D to pilot production, LibraGen is fulfilling a market need by giving its customers high performance and competitive synthesis solutions. Since the company was set up in 2001, LibraGen's reactivity and innovation has resulted in its becoming the exclusive producer of active enzymes for a number of third parties. More information:

About DSM Pharmaceutical Products

DSM Pharmaceutical Products is a global provider of high quality custom contract manufacturing and development services to the pharmaceutical and biopharmaceutical industries. DSM contract manufacturing services include: chemical development, registered intermediates, registered starting materials, active pharmaceutical ingredients (API's), fermentation, mammalian cell production of monoclonal antibodies and proteins, formulation development, clinical trial manufacturing and finished dose form manufacturing of solids, semi-solids, and scheduled drugs, aseptic liquid and lyophilized products. More information:

DSM - the Life Sciences and Materials Sciences Company

Royal DSM N.V. creates innovative products and services in Life Sciences and Materials Sciences that contribute to the quality of life. DSM's products and services are used globally in a wide range of markets and applications, supporting a healthier, more sustainable and more enjoyable way of life. End markets include human and animal nutrition and health, personal care, pharmaceuticals, automotive, coatings and paint, electrics and electronics, life protection and housing. DSM has annual sales of almost EUR 8.8 billion and employs some 23,000 people worldwide. The company is headquartered in the Netherlands, with locations on five continents. DSM is listed on Euronext Amsterdam. More information:

Forward-looking statements

Any forward-looking statements contained in this press release that involve inherent risks and uncertainties are based on current expectations, estimates and projections of the management of DSM and information currently available. The statements involve certain risks and uncertainties that are difficult to predict and therefore DSM does not guarantee that its expectations will be realized. Furthermore, DSM has no obligation to update any statements contained in this press release.

For further information please contact:

DSM Pharmaceutical Products

Guy Tiene

Director, Marketing & Communications

Tel: +1-973-257-8160

DSM Pharmaceutical Products

Oliver May

Competence Manager Biocatalysis

Tel: +31 (46) 4760551


Renaud Nalin

Chief Executive Officer

Tel: +33 562 193 290


Fabrice Lefevre

Chief Scientific Officer

Tel: +33 562 193 297

SOURCE DSM Pharmaceutical Products
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. ImmuneRegen BioSciences Reports Material Transfer Agreement with VaxGen, Inc.
2. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
3. CellCyte Genetics Corp. Enters Collaborative Research Agreement With Cleveland Clinic Foundation to Qualify Stem Cell Delivery in Damaged Heart Tissue
4. Intellect Neurosciences, Inc. and CHDI, Inc. Enter Into Compound Testing Agreement to Evaluate OXIGON(TM) as a Potential Treatment for Huntington Disease
5. Baxa Corporation Extends Global Reach With New Distribution Agreements in Colombia and the Dominican Republic
6. Quark Pharmaceuticals Signs Collaboration Agreement With University of Michigan for Development of Proprietary SiRNA Compounds for Noise-Induced Hearing Loss
7. Lilly and Glenmark Pharmaceuticals Announce License Agreement
8. Siemens Medical Solutions Diagnostics Inks Agreement with KreLo Medical Diagnostics to Expand Thyroid Immunoassay Menu
9. Tacere Therapeutics Enters Collaboration and License Agreement With Pfizer To Develop and Commercialize RNAi Hepatitis C Drug
10. Juvaris BioTherapeutics Announces Cooperative Research and Development Agreement With The Centers for Disease Control and Prevention
11. Beckman Coulter Announces Licensing Agreements for Molecular Tests with National University of Ireland, Galway
Post Your Comments:
(Date:11/27/2015)... , Nov. 27, 2015 Research and Markets ... "Global Intrauterine Devices Market 2015-2019" report to ... --> In this report, the author the present ... market for 2015-2019. To calculate the market size, the ... type of products: Hormonal IUDs and copper IUDs. The ...
(Date:11/26/2015)... the Netherlands , November 26, 2015 ... A new combination approach blends immunotherapy with ... A new combination approach blends immunotherapy with Bremachlorin-photodynamic ... A new combination approach blends immunotherapy with Bremachlorin-photodynamic ... the Netherlands has found that immunotherapy can ...
(Date:11/26/2015)... Nov. 26, 2015 Research and Markets ... the "2016 Future Horizons and Growth Strategies ... Supplier Shares, Country Segment Forecasts, Competitive Intelligence, Emerging ... --> --> This ... the Japanese therapeutic drug monitoring market, including emerging ...
Breaking Medicine Technology:
(Date:11/28/2015)... ... 28, 2015 , ... StatRad , a leading provider ... and Claude Hooton to its board of directors. The announcement comes as the ... Annual Meeting and continues to strategically transform its focus from being a teleradiology ...
(Date:11/28/2015)... ... 2015 , ... Pixel Film Studios is back again with ProPanel: Pulse ... are endless. Users have full control over angle of view, speed method, start point, ... sure to get heads to turn. , ProPanel: Pulse offers fully customizable pulsating shape ...
(Date:11/27/2015)... ... 2015 , ... According to an article published November 15th by ... handling security in light of the recent terrorist attacks in Paris, other cities are ... an attack from reaching U.S. soil. Especially around special events that may be high-profile ...
(Date:11/27/2015)... (PRWEB) , ... November 27, 2015 , ... ... filthy the toilets were," said an inventor from Hillside, N.J. "Many people catch ... seat cover so that individuals will always be protected from germs." , He ...
(Date:11/27/2015)... ... 2015 , ... MPWH, the No.1 Herpes-only dating community in the world, revealed that over 50% ... More than 3.7 billion people under the age of 50 – or 67% of the ... first global estimates of HSV-1 infection . , "The data shocks us highly!" said ...
Breaking Medicine News(10 mins):